Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hypochondroplasia is characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
Features include always present findings: Short long bone, Widened interpedicular distance, Depressed nasal bridge, and Prominent forehead and others; and common findings: Short femoral neck, Excessive inward curve of the lower back (lumbar hyperlordosis), and Macrocephaly. 19 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 3 | Short long bone, Short femoral neck, Excessive inward curve of the lower back (lumbar hyperlordosis) |
FGFR3 encodes fibroblast growth factor receptor 3 (806 aa). Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Highest expression in Skin Not Sun Exposed Suprapubic (364.5 TPM) and Skin Sun Exposed Lower leg (356.5 TPM).
Hypochondroplasia is caused by mutations in the FGFR3 gene on chromosome 4.
FGFR3 is classified as a druggable target (Cell Surface, Clinically Actionable, Drug Resistance, Druggable Genome, Kinase, and Tyrosine Kinase categories) with score 1.6.
The clinical and radiologic diagnostic criteria for hypochondroplasia remain controversial for several reasons, including the following:
No single radiologic or clinical feature is unique to hypochondroplasia.
The expression of many of the established diagnostic features in affected individuals is variable.
Locus heterogeneity is possible.
No approved treatments are currently available for hypochondroplasia. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for hypochondroplasia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for hypochondroplasia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. Hypochondroplasia: Recommended Surveillance
9 clinical trials registered, 5 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05328050](https://clinicaltrials.gov/study/NCT05328050) |
Data assembled from 10 of 12 sources · Last updated Sep 19, 2026, 6:34 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Arms and legs | 3 | Aplasia/hypoplasia of the extremities, Trident hand, Disproportionate short-limb short stature |
Head and neck | 2 | Craniosynostosis, Macrocephaly |
Brain and nerves | 2 | Depressed nasal bridge, Intellectual disability |
Growth and development | 1 | Disproportionate short-limb short stature |
Growth. The most common presenting feature of children with hypochondroplasia is short stature with disproportionate limbs and relative macrocephaly. Birth weight and length are often within the normal range and the disproportion in limb-to-trunk length is usually mild and easily overlooked during infancy. Typically, these children present to pediatricians or pediatric endocrinologists as toddlers or at early school age with decreased growth velocity leading to short stature. There is a lack of the pubertal growth spurt when the height difference from those with hypochondroplasia and those with average stature may increase.
Source: GeneReviews — "Hypochondroplasia"
Because of evidence that the height range in hypochondroplasia may overlap that of the unaffected population, individuals with hypochondroplasia may not be recognized as having a skeletal dysplasia unless an astute physician recognizes their disproportionate short stature. To date, however, all reported individuals with an FGFR3 pathogenic variant have had demonstrable radiographic changes compatible with hypochondroplasia or one of the other phenotypes known to be associated with pathogenic variants in this gene .
Source: GeneReviews — "Hypochondroplasia"
Hypochondroplasia should be suspected in individuals wit...
Source: GeneReviews — "Hypochondroplasia"
Numerous forms of skeletal dysplasia with disproportionate limbs are recognized and are characterized by clinical and radiologic features that distinguish them from hypochondroplasia and achondroplasia. Many of these disorders are quite rare. The diagnosis of hypochondroplasia is seldom made at birth unless a prior family history exists. Most affected individuals present with short stature as toddlers or young school-age children. Inappropriate diagnoses of hypochondroplasia are often made because the disorder is considered to be relatively common and the radiologic features are variable and may be subtle. Conditions with a known genetic etiology that may be confused with hypochondroplasia are summarized in . Table 3. Genes of Interest in the Differential Diagnosis of Hypochondroplasia
Gene(s) | Disorder | MOI |
|---|---|---|
B3GALT6 | Mild forms of spondyloepimetaphyseal dysplasia (e.g., B3GALT6-related spondyloepimetaphyseal dysplasia w/joint laxity [Beighton type]) (OMIM 271640) | AR COL10A1 |
PTH1R | Mild forms of metaphyseal chondrodysplasia (e.g., Schmid metaphyseal chondrodysplasia PTHR1-related Jansen type metaphyseal chondrodysplasia) | AD |
FGFR3 | Achondroplasia (See .) | AD |
GNAS | Pseudohypoparathyroidism pseudopseudohypoparathyroidism (See Disorders of GNAS Inactivation.) | AD1 |
SHOX | Mild forms of mesomelic dysplasia (e.g., SHOX-related mesomelic dysplasia [Langer type]) (OMIM 249700) | Pseudo AR Leri-Weill dyschondrosteosis (See SHOX Deficiency Disorders.) |
Source: GeneReviews — "Hypochondroplasia"
Genetic testing for FGFR3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypochondroplasia has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
infigratinib | infigratinib | QED Therapeutics, Inc | 2025 | — | Designated |
vosoritide | vosoritide | BioMarin Pharmaceutical Inc. | 2023 | — | Designated |
infigratinib is referenced in active clinical trials for hypochondroplasia (designated 2025).
vosoritide is referenced in active clinical trials for hypochondroplasia (designated 2023).
Gene therapy approaches for hypochondroplasia have been reported in the published literature.
Management of children with hypochondroplasia usually does not differ significantly from that of children with average stature except for genetic counseling issues and dealing with parental concerns about short stature. However, because the phenotype of FGFR3-related hypochondroplasia may overlap with that of achondroplasia, recommendations for the management of achondroplasia as outlined by the American Academy of Pediatrics Committee on Genetics should be considered in children with hypochondroplasia who exhibit more severe phenotypic features.
To establish the extent of disease and needs in an individual diagnosed with hypochondroplasia, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Hypochondroplasia: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Measurement of height, weight, head circumference | Plot growth parameters on hypochondroplasia-standardized growth curves (full text).
| Clinical assessment for truncal weakness or evidence of thoracolumbar kyphosis | Lateral spine radiographs to evaluate for thoracolumbar kyphosis if indicated
Clinical assessment for genu varum | Referral to orthopedist if bowing interferes w/walking
| • Assess for signs/symptoms of sleep apnea; refer for polysomnography if needed.
Source: GeneReviews — "Hypochondroplasia"
9 trials found
Evaluation |
|---|
Frequency |
|---|
Growth | Height, weight, head circumference | Monitor using hypochondroplasia-standardized growth curves at every well-child visit (full text). |
Spinal cord compression | Neurologic exam for signs/symptoms | At routine well-child visits (every 6-12 mos) through adulthood MRI of foramen magnum if evidence of severe hypotonia, spinal cord compression, or central sleep apnea |
Sleep apnea | Assessment for signs/symptoms | At routine well-child visits (every 6-12 mos) through adulthood |
Thoracolumbar kyphosis | Physical exam | At routine well-child visits (every 6-12 mos) through age 3 yrs |
Genu varum | Physical exam w/orthopedic referral if bowing interferes w/walking | As needed |
Development | Assessment of developmental milestones | Monitor every 6-12 mos during early childhood. Assessment of social adjustment |
Source: GeneReviews — "Hypochondroplasia"
Phenotype severity distribution: 5 always present features, 3 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
— |
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
RECRUITING |
[NCT07073014](https://clinicaltrials.gov/study/NCT07073014) | Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia | PHASE3 | BioMarin Pharmaceutical | ENROLLING_BY_INVITATION |
[NCT07126262](https://clinicaltrials.gov/study/NCT07126262) | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months | PHASE2 | BioMarin Pharmaceutical | RECRUITING |
[NCT07393373](https://clinicaltrials.gov/study/NCT07393373) | Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia | PHASE2 | QED Therapeutics, a BridgeBio company | ENROLLING_BY_INVITATION |
[NCT06873035](https://clinicaltrials.gov/study/NCT06873035) | An Interventional Study of Infigratinib in Children With Hypochondroplasia | PHASE2 | QED Therapeutics, a BridgeBio company | ENROLLING_BY_INVITATION |
30 publications have been identified in PubMed for hypochondroplasia. Research spans Diagnostic / Biomarker (17%), Case Report / Case Series (17%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 5 | 17% |
Patient case studies | 5 | 17% |
Disease patterns and progression | 5 | 17% |
Research summaries | 4 | 13% |
Laboratory research | 4 | 13% |
New treatment approaches | 4 | 13% |
Clinical study results | 3 | 10% |
Kanakatti Shankar R (2026). [PMID: 41157964](https://pubmed.ncbi.nlm.nih.gov/41157964/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Candler TP (2026). [PMID: 41565440](https://pubmed.ncbi.nlm.nih.gov/41565440/). *Arch Dis Child*. [Review / Meta-Analysis]
Irving M (2026). [PMID: 41762373](https://pubmed.ncbi.nlm.nih.gov/41762373/). *Adv Ther*. [Diagnostic / Biomarker]
Mammadova N (2026). [PMID: 42053849](https://pubmed.ncbi.nlm.nih.gov/42053849/). *Mol Biol Rep*. [Case Report / Case Series]
Galetaki D (2026). [PMID: 39427650](https://pubmed.ncbi.nlm.nih.gov/39427650/). *Horm Res Paediatr*. [Clinical Trial Publication]
Legeai-Mallet L (2026). [PMID: 41593746](https://pubmed.ncbi.nlm.nih.gov/41593746/). *J Bone Miner Res*. [Gene Therapy / Novel Therapeutics]
Ursachi VC (2026). [PMID: 41582902](https://pubmed.ncbi.nlm.nih.gov/41582902/). *J Bone Miner Res*. [Diagnostic / Biomarker]
Jumayeva G (2026). [PMID: 39967053](https://pubmed.ncbi.nlm.nih.gov/39967053/). *Cleft Palate Craniofac J*. [Case Report / Case Series]
Pattani N (2026). [PMID: 41956799](https://pubmed.ncbi.nlm.nih.gov/41956799/). *J Med Genet*. [Diagnostic / Biomarker]
Cheung MS (2026). [PMID: 41040055](https://pubmed.ncbi.nlm.nih.gov/41040055/). *Am J Med Genet A*. [Diagnostic / Biomarker]
AI-curated news mentioning hypochondroplasia
Updated Sep 9, 2026
A Phase 3 trial of vosoritide in children with hypochondroplasia has been conducted, focusing on its efficacy and safety. The results could provide valuable insights into treatment options for this rare skeletal dysplasia.
The CANOPY HCH-3 study is a phase 3 trial designed to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia. This randomized, double-blind, placebo-controlled study aims to provide critical data on the treatment's impact.
An international Delphi consensus has established recommendations for the diagnosis of hypochondroplasia, a rare skeletal dysplasia. These guidelines aim to standardize diagnostic criteria and improve patient outcomes.
BioMarin's Phase 3 trial of Voxzogo for hypochondroplasia demonstrated efficacy significantly exceeding previous results for achondroplasia. This positive outcome follows earlier safety concerns and positions Voxzogo favorably in the rare skeletal disorder market.